Literature DB >> 29654757

Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications.

Joyce R Chong1, Ping Xiang1, Wei Wang1, Tatsuma Hind2, Wee Siong Chew1, Wei-Yi Ong3, Mitchell K P Lai4, Deron R Herr5.   

Abstract

It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is responsible for homeostatic maintenance of hundreds of distinct SL species. This pathway is perturbed in a number of pathological processes, resulting in derangement of the "sphingolipidome." Recently, advances in mass spectrometry (MS) techniques have made it possible to characterize the sphingolipidome in large-scale clinical studies, allowing for the identification of specific SL molecules that mediate pathological processes and/or may serve as biomarkers. This manuscript provides an overview of the functions of SLs, and reviews previous studies that have used MS techniques to identify changes to the sphingolipidome in non-metabolic diseases.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Cancer; Ceramide; Dementia; Lipidomics; Neutral sphingomyelinase 2 (nSMase2); Sphingolipid; Sphingomyelin; Sphingomyelinase; Sphingosine-1-phosphate; Stroke

Mesh:

Substances:

Year:  2018        PMID: 29654757     DOI: 10.1016/j.bbrc.2018.04.075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence.

Authors:  Wee Siong Chew; Federico Torta; Shanshan Ji; Hyungwon Choi; Husna Begum; Xueling Sim; Chin Meng Khoo; Eric Yin Hao Khoo; Wei-Yi Ong; Rob M Van Dam; Markus R Wenk; E Shyong Tai; Deron R Herr
Journal:  JCI Insight       Date:  2019-06-04

Review 2.  Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network.

Authors:  Jan Skácel; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

3.  Editorial for BBRC lipidomics special issue.

Authors:  Sarah Spiegel; James Ntambi
Journal:  Biochem Biophys Res Commun       Date:  2018-10-07       Impact factor: 3.575

4.  Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment.

Authors:  Xin Ying Chua; Yuek Ling Chai; Wee Siong Chew; Joyce R Chong; Hui Li Ang; Ping Xiang; Kaddy Camara; Amy R Howell; Federico Torta; Markus R Wenk; Saima Hilal; Narayanaswamy Venketasubramanian; Christopher P Chen; Deron R Herr; Mitchell K P Lai
Journal:  Alzheimers Res Ther       Date:  2020-09-30       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.